Previously, the FBXW7/SCF complex was shown to target mTOR for ubiquitylation and proteasomal degradation [Mao et al., 2008] and mTOR activation is common in sporadic RCC and mTOR inhibitors have shown promise in clinical trials for the treatment of metastatic RCC [Anandappa et al., 2010; Gerullis et al., 2010; Pinto Marín et al., 2012]. The gene discussed is FBXW7; the disease is renal cell carcinoma.